

October 29, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Symbol: STAR

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Outcome of Board Meeting of the Company held on October 29, 2026

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

We are pleased to enclose the Unaudited Financial Results (Consolidated and Standalone) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended September 30, 2026, as approved by the Board of Directors of the Company at their meeting held today i.e., October 29, 2026.

Board Meeting commenced at 16:45 hrs (IST) and concluded at 18:15 hrs IST.

The above information shall be made available on the website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited**,

MANJULA
RAMAMURTHY

Digitally signed by
MANJULA RAMAMURTHY
Date: 2026.10.29 18:31:48
+05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

Limited Review Report on unaudited consolidated financial results of Strides Pharma Science Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Strides Pharma Science Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Strides Pharma Science Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associates and joint venture for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I of this limited review report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report (Continued)

Strides Pharma Science Limited

6. We did not review the interim financial information of 2 Subsidiaries included in the Statement, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 6,861 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 2,224 million and Rs. 4,414 million, total net profit after tax (before consolidation adjustments) of Rs. 76 million and Rs. 429 million and total comprehensive income (before consolidation adjustments) of Rs. 76 million and Rs. 429 million, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. 167 million for the period from 1 April 2026 to 30 September 2026. as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of 25 Subsidiaries which have not been reviewed, whose interim financial information reflect total assets (before consolidation adjustments) of Rs. 49,386 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 1,668 million and Rs. 3,661 million, total net loss after tax (before consolidation adjustments) of Rs. 244 million and Rs. 172 million and total comprehensive loss (before consolidation adjustments) of Rs. 460 million and Rs. 146 million, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. 325 million for the period from 01 April 2026 to 30 September 2026. as considered in the Statement. The Statement also includes the Group's share of net profit/(loss) after tax of Rs. 9 million and Rs. (4 million) and total comprehensive income/(loss) of Rs. 9 million and Rs. (4 million), for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively as considered in the Statement, in respect of 4 associates and a joint venture, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**G
PRAKASH
SH** Digitally signed
by G PRAKASH
Date:
2026.10.29
17:23:10
+05'30'

G Prakash

Partner

Bangalore

29 October 2026

Membership No.: 099696

UDIN:26099696LPDUPC3899

Limited Review Report (Continued)

Strides Pharma Science Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sl. No	Name of component	Relationship
1	Amexel Pte. Ltd, Singapore	Subsidiary
2	Aponia Laboratories Inc., United States	Associate
3	Arco Lab Private Limited, India	Subsidiary
4	Asaco Trinity Proprietary Limited, South Africa	Associate (Associate w.e.f 22 May 2026)
5	Beltapharm S.R.L, Italy	Subsidiary
6	Fairmed Healthcare GmbH, Germany	Subsidiary
7	Neviton Softech Private Limited, India	Subsidiary
8	Neviton Technologies Inc., USA	Subsidiary
9	Pharmapar Inc., Canada	Subsidiary
10	Pivot Path Private Limited	Associate (Subsidiary till 30 June 2026)
11	Sihuan Strides (HK) Ltd., Hong Kong	Joint venture
12	Strides Arcolab International Ltd, United Kingdom	Subsidiary
13	Strides Consumer LLC (USA)	Subsidiary
14	Strides Consumer Private Limited, India	Subsidiary
15	Strides Foundation Trust, India	Trust
16	Strides Global Consumer Healthcare Limited, UK	Subsidiary
17	Strides Lifesciences Limited, Nigeria	Subsidiary
18	Strides Netherlands B.V., Netherlands	Subsidiary
19	Strides Nordic ApS, Denmark	Subsidiary

Limited Review Report (Continued)**Strides Pharma Science Limited**

20	Strides Pharma (Cyprus) Limited, Cyprus	Subsidiary
21	Strides Pharma Asia Pte. Ltd., Singapore	Subsidiary
22	Strides Pharma Canada Inc., Canada	Subsidiary
23	Strides Pharma Global (UK) Ltd, United Kingdom	Subsidiary
24	Strides Pharma Global Pte. Limited, Singapore	Subsidiary
25	Strides Pharma Inc., USA	Subsidiary
26	Strides Pharma International AG, Switzerland (formerly, Fairmed Healthcare AG, Switzerland)	Subsidiary
27	Strides Pharma International Limited, Cyprus	Subsidiary
28	Strides Pharma New Zealand Pty Limited	Subsidiary
29	Strides Pharma SA Pty Ltd, South Africa	Subsidiary
30	Strides Pharma Science Limited, India	Holding
31	Strides Pharma Science Pty Ltd, Australia	Subsidiary
32	Strides Pharma UK Ltd, United Kingdom	Subsidiary
33	SVADS Holdings SA, Switzerland	Subsidiary
34	Trinity Pharma (Pty) Ltd, South Africa	Subsidiary
35	UCL Brands Limited, Kenya	Subsidiary
36	Universal Corporation Limited, Kenya	Associate
37	Vensun Pharmaceuticals, Inc., United States	Subsidiary



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

Rs. in Million

Sl. No.	Particulars	3 Months ended September 30, 2026	Preceding 3 Months ended June 30, 2026	Corresponding 3 Months ended in the previous year September 30, 2025	Year to date figures for the period ended September 30, 2026	Year to date figures for the previous period ended September 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
	Continuing operations						
I	Revenue from operations	14,297.34	12,654.07	12,208.31	26,951.41	23,405.67	48,586.83
II	Other income (Refer Note 7)	40.83	48.90	271.40	89.73	357.23	1,507.13
III	Total income (I + II)	14,338.17	12,702.97	12,479.71	27,041.14	23,762.90	50,093.96
IV	Expenses						
	(a) Cost of materials consumed	5,649.47	4,147.15	4,297.56	9,796.62	6,903.36	15,589.19
	(b) Purchases of stock-in-trade	1,809.73	1,663.81	418.00	3,473.54	1,627.13	3,615.36
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,164.92)	(859.08)	437.05	(2,024.00)	1,064.95	382.75
	(d) Employee benefits expense	2,382.74	2,429.86	2,267.81	4,812.60	4,522.99	9,289.57
	(e) Finance costs	465.41	405.61	461.27	871.02	935.87	1,785.45
	(f) Depreciation and amortisation expense	572.15	563.99	496.43	1,136.14	985.29	2,024.01
	(g) Other expenses	3,111.18	2,974.59	2,472.22	6,085.77	4,790.83	10,457.03
	Total expenses (IV)	12,825.76	11,325.93	10,850.34	24,151.69	20,830.42	43,143.36
V	Profit before exceptional items and tax (III - IV)	1,512.41	1,377.04	1,629.37	2,889.45	2,932.48	6,950.60
VI	Exceptional items (Refer note 4)	(17.04)	631.97	(87.72)	614.93	(171.39)	(268.43)
VII	Profit before tax (V + VI)	1,495.37	2,009.01	1,541.65	3,504.38	2,761.09	6,682.17
VIII	Share of profit/(loss) of joint venture and associates, net of taxes - (net)	8.99	(12.85)	(10.48)	(3.86)	(9.49)	4.69
IX	Profit before tax (VII + VIII)	1,504.36	1,996.16	1,531.17	3,500.52	2,751.60	6,686.86
X	Tax expense						
	- Current tax	216.79	290.06	227.39	506.85	336.19	778.76
	- Deferred tax	(53.61)	51.17	(11.46)	(2.44)	44.24	162.90
	Total tax expense (X)	163.18	341.23	215.93	504.41	380.43	941.66
XI	Profit for the period/year (IX - X)	1,341.18	1,654.93	1,315.24	2,996.11	2,371.17	5,745.20



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

Rs. in Million

Sl. No.	Particulars	3 Months ended September 30, 2026	Preceding 3 Months ended June 30, 2026	Corresponding 3 Months ended in the previous year September 30, 2025	Year to date figures for the period ended September 30, 2026	Year to date figures for the previous period ended September 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
XII	Other comprehensive income						
A	(i) Items that will not be reclassified to statement of profit and loss	(274.01)	322.53	(657.98)	48.52	162.06	(467.01)
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	58.44	(80.81)	165.50	(22.37)	(40.82)	91.12
B	(i) Items that may be reclassified to statement of profit and loss	645.13	125.67	144.50	770.80	(115.03)	615.31
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	(37.97)	(78.22)	105.48	(116.19)	138.18	200.81
	Total other comprehensive income for the period/year (XII)	391.59	289.17	(242.50)	680.76	144.39	440.23
XIII	Total comprehensive income for the period/year (XI + XII)	1,732.77	1,944.10	1,072.74	3,676.87	2,515.56	6,185.43
	Profit for the period/year attributable to:						
	- Owners of the Company	1,308.36	1,569.14	1,275.34	2,877.50	2,271.42	5,561.93
	- Non-controlling interests	32.82	85.79	39.90	118.61	99.75	183.27
		1,341.18	1,654.93	1,315.24	2,996.11	2,371.17	5,745.20
	Other comprehensive income for the period/year						
	- Owners of the Company	385.46	281.83	(252.10)	667.29	131.80	415.09
	- Non-controlling interests	6.13	7.34	9.60	13.47	12.59	25.14
		391.59	289.17	(242.50)	680.76	144.39	440.23
	Total comprehensive income for the period/year						
	- Owners of the Company	1,693.82	1,850.97	1,023.24	3,544.79	2,403.22	5,977.02
	- Non-controlling interests	38.95	93.13	49.50	132.08	112.34	208.41
		1,732.77	1,944.10	1,072.74	3,676.87	2,515.56	6,185.43
	Earnings per equity share (face value of Rs. 10/- each)						
	(1) Basic (in Rs.)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(2) Diluted (in Rs.)	14.19	17.02	13.84	31.22	24.64	60.34
		14.19	17.02	13.84	31.22	24.64	60.34
	See accompanying notes to the Financial Results						



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

CONSOLIDATED BALANCE SHEET

Rs. in Million

	Particulars	As at	As at
		September 30,	March 31, 2026
		2026	
		UNAUDITED	AUDITED
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment	9,103.67	9,141.97	
(b) Capital work-in-progress	2,263.10	1,611.23	
(c) Right-of-use assets	478.61	782.33	
(d) Investment property	2.14	2.43	
(e) Goodwill	6,007.12	5,944.24	
(f) Other Intangible assets	5,349.56	5,134.95	
(g) Intangibles assets under development	3,118.66	2,861.58	
(h) Investment in associates and joint ventures	582.67	124.74	
(i) Financial assets			
(i) Investments	2,877.96	2,788.82	
(ii) Other financial assets	1,155.23	1,090.60	
(j) Deferred tax assets (net)	2,694.52	2,838.62	
(k) Income tax assets (net)	223.23	470.10	
(l) Other non-current assets	660.05	347.32	
Total non-current assets	34,516.52	33,138.93	
II Current assets			
(a) Inventories	18,734.73	16,347.94	
(b) Financial assets			
(i) Trade receivables	14,639.62	12,889.64	
(ii) Cash and cash equivalents	1,373.35	1,886.96	
(iii) Other balances with banks	101.46	244.46	
(iv) Loans	79.85	81.36	
(v) Other financial assets	1,629.57	1,972.09	
(c) Other current assets	3,813.06	2,705.48	
Total current assets	40,371.64	36,127.93	
Assets held for sale	-	5.46	
Total Assets	74,888.16	69,272.32	



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

CONSOLIDATED BALANCE SHEET

		Rs. in Million	
	Particulars	As at September 30, 2026	As at March 31, 2026
		UNAUDITED	AUDITED
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	921.73	921.73
	(b) Other equity	33,243.00	30,153.92
	Equity attributable to owners of the Company	34,164.73	31,075.65
	Non- Controlling interests	540.25	417.72
	Total equity	34,704.98	31,493.37
II	Liabilities		
1	Non-current liabilities		
	(a) Financials liabilities		
	(i) Borrowings		
	- Borrowings US revolver facility	2,634.27	3,010.50
	- Borrowings others	3,025.75	2,512.66
	(ii) Lease Liabilities	302.81	518.40
	(iii) Other financial liabilities	363.96	312.13
	(b) Provisions	1,153.87	1,263.64
	(c) Deferred tax liabilities (net)	1,352.73	1,206.69
	Total non-current liabilities	8,833.39	8,824.02
2	Current liabilities		
	(a) Financials liabilities		
	(i) Borrowings	12,811.21	11,163.74
	(ii) Lease liabilities	274.64	374.53
	(iii) Trade payables		
	(a) total outstanding dues of micro enterprises and small enterprises and	870.98	464.01
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	13,456.24	12,632.79
	(iv) Other financial liabilities	1,285.45	2,122.79
	(b) Other current liabilities	1,382.42	749.53
	(c) Provisions	950.78	963.59
	(d) Current tax liabilities (net)	318.07	483.95
	Total current liabilities	31,349.79	28,954.93
	Total Liabilities	40,183.18	37,778.95
	Total Equity and liabilities	74,888.16	69,272.32

-



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

CONSOLIDATED STATEMENT OF CASH FLOW

Sl. No.	Particulars	Rs. In Million		
		For the half year ended September 30, 2026	For the previous half year ended September 30, 2025	For the previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	AUDITED
A.	Cash flow from operating activities			
	Profit / (loss) before tax from:			
	Continuing operations	3,500.52	2,751.60	6,686.86
		3,500.52	2,751.60	6,686.86
	Adjustments for:			
	- Depreciation and amortisation expense	1,136.14	985.29	2,024.01
	- Share of (profit)/loss of joint ventures and associates	3.86	9.49	(4.69)
	- Gain/(loss) on sale of property, plant and equipment, other intangible assets and investment property (net)	22.59	(6.16)	(1,042.40)
	- Share based compensation expense	0.88	1.68	3.14
	- Business combination and restructuring expenses	-	2.89	4.62
	- Interest expense on borrowings & others	871.02	935.87	1,785.45
	- Interest and dividend income	(79.92)	(325.31)	(404.81)
	- Rental income	(3.83)	(11.06)	(12.69)
	- Liability / provision no longer required written back	(0.07)	-	(0.09)
	- Loss allowance on trade receivables	(30.61)	3.97	(63.09)
	- Movement in inventory obsolescence	687.15	-	173.28
	- Impairment and write down of assets	-	(0.01)	34.70
	- Gain on loss of control in subsidiary	(742.07)	-	-
	- Derecognition of ROU asset and liability	-	(9.25)	(35.15)
	- Unrealised exchange gain / (loss) (net)	(315.07)	(484.01)	(408.34)
	Operating profit before working capital changes	5,050.59	3,854.99	8,740.80
	Changes in working capital:			
	Decrease / (Increase) in trade and other receivables	(2,861.83)	362.96	(1,093.24)
	Increase in inventories	(2,803.47)	(1,493.58)	(3,018.48)
	Decrease in trade and other payables	2,005.14	1,096.19	3,107.23
	Net change in working capital	(3,660.16)	(34.43)	(1,004.49)
	Cash generated from operations	1,390.43	3,820.56	7,736.31
	Income taxes refund received, net	(324.71)	94.22	(711.12)
	Net cash generated from operating activities	1,065.72	3,914.78	7,025.19
	A			



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026
CONSOLIDATED STATEMENT OF CASH FLOW**

Sl. No.	Particulars	Rs. In Million		
		For the half year ended September 30, 2026	For the previous half year ended September 30, 2025	For the previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	AUDITED
B.	Cash flow from investing activities			
	Capital expenditure for property, plant and equipment and intangible assets, including capital advance	(2,664.51)	(1,491.91)	(4,179.35)
	Proceeds from sale of property, plant and equipment and intangible assets	4.57	31.67	63.90
	Proceeds from sale of investment property (net of expenses)	0.19	-	1,128.70
	Receipt/(Refund) of advance for sale of investment property	-	(50.00)	(50.00)
	Purchase of long-term investments including investment in associates	-	-	(12.60)
	Consideration paid towards acquisition of non-controlling interest in subsidiary and business combinations, net of cash acquired	(16.52)	-	(217.74)
	Proceeds from sale of investments in mutual funds	-	10.26	921.67
	Proceeds from loss of control in subsidiary	750.00	-	-
	Deferred consideration received from sale of business	-	-	513.69
	Deferred consideration settled with trade payables	-	-	106.45
	(Investment) / proceeds in fixed deposits with maturity of more than 3 months, net	67.66	(9.60)	(63.54)
	Rental income from investment property	3.83	11.06	12.69
	Interest and dividends received (net of tax on dividend)	31.96	19.91	45.77
	Net cash utilised in investing activities	(1,822.82)	(1,478.61)	(1,730.36)
C.	Cash flow from financing activities			
	Proceeds from issue of equity shares	-	3.87	3.86
	Proceeds from Share application money pending allotment	4.25	-	-
	Proceeds from long-term borrowings	827.82	574.99	1,705.00
	Repayment of long-term borrowings	(333.22)	(481.79)	(919.37)
	Net decrease in U.S revolver facility	(439.54)	(1,208.06)	(1,600.50)
	Net increase / (decrease) in working capital and short-term borrowings	1,643.56	242.77	(1,308.01)
	Lease payments (Principal)	(148.73)	(132.67)	(272.99)
	Lease payments (Interest)	(35.04)	(48.11)	(94.12)
	Dividends paid	(460.87)	(368.65)	(368.65)
	Interest paid on borrowings	(805.96)	(908.69)	(1,679.31)
	Net cash generated/(utilised) in financing activities	252.27	(2,326.34)	(4,534.09)



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026
CONSOLIDATED STATEMENT OF CASH FLOW**

Sl. No.	Particulars	Rs. In Million		
		For the half year ended September 30, 2026	For the previous half year ended September 30, 2025	For the previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	AUDITED
	Net increase/(decrease) in cash and cash equivalents during the year (A+B+C)	(504.83)	109.83	760.74
	Cash and cash equivalents at the beginning of the year	1,886.96	1,125.64	1,125.64
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	(8.36)	(3.39)	0.58
	Cash and cash equivalents pursuant to loss of control in a subsidiary	(0.42)	-	-
	Cash and cash equivalents at the end of the period/year*	1,373.35	1,232.08	1,886.96
	* Comprises:			
	Cash on hand	3.14	3.92	4.64
	Balance with banks:			
	- In current accounts	1,074.42	1,059.10	1,659.84
	- In deposit accounts	40.56	50.18	51.87
	- Funds-in-transit	255.23	118.88	170.61
	Total	1,373.35	1,232.08	1,886.96

**STRIDES PHARMA SCIENCE LIMITED**

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS**FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026****Notes:**

- These consolidated financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 29, 2026. The statutory auditor has carried out a limited review of the above results and issued unmodified opinion.
- Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Group's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments.

The CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. "Pharmaceutical". Consequently, the Company has only one reportable segment and accordingly disclosures made in these results at the Group level suffice for compliance with the requirements of Ind AS 108.

Pharmaceutical segment represents the business of development, manufacture and commercialization of pharmaceutical products other than biological drugs.

4 Exceptional Items:

							Rs. in Million
	Particulars	3 Months ended September 30, 2026	Preceding 3 Months ended June 30, 2026	Corresponding 3 Months ended in the previous year September 30, 2025	Year to date figures for the period ended September 30, 2026	Year to date figures for the previous period ended September 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
	- Expenses related to product recall and settlements (Refer note 6)	(17.04)	(110.10)	(86.34)	(127.14)	(168.51)	(228.79)
	- Impairment and write down of assets	-	-	0.03	-	0.01	(34.70)
	- Business combination and restructuring expenses (Refer note 5)	-	742.07	(1.41)	742.07	(2.89)	(4.94)
	Total	(17.04)	631.97	(87.72)	614.93	(171.39)	(268.43)

- On March 19, 2025, the Board of Directors of the Company approved the demerger of the Life Sciences and Digital Innovation capabilities business of Arco Lab Private Limited ("Arco Lab"), a subsidiary of the Company, into Pivot Path Private Limited ("Pivot Path"), subsidiary of Arco Lab, pursuant to a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The Scheme, approved by the Board of Directors of Arco Lab on May 15, 2025, with an appointed date of April 10, 2025, was approved by the Hon'ble National Company Law Tribunal (NCLT) on June 1, 2026.

In the previous quarter, the Board of Directors of the Company, approved the dilution of the Group's controlling stake in Pivot Path to incoming investors for an aggregate consideration of ₹1,000 million. Upon completion of the transaction, the Group's shareholding in Pivot Path reduced to 19.95%, resulting in a loss of control over Pivot Path and the recognition of the retained interest as an investment in associate at fair value as on the date of loss of control. As part of the transaction, the Company entered into a five-year Master Services Agreement with Pivot Path containing minimum revenue commitment and annual price escalation arrangement. The Group recognized a net gain of ₹742.07 million on the transaction, including the fair value remeasurement of its retained interest in Pivot Path, which has been disclosed as an exceptional item in these financial results.

- On March 31, 2020, US Food and Drug Administration (USFDA or the Agency) issued letters to all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescription(Rx) and over-the-counter (OTC) ranitidine drugs from the market immediately. This step was based on their ongoing investigation of the N-Nitrosodimethylamine (NDMA) impurity in ranitidine medications. As a result, effective April 1, 2020, the Group had ceased further distribution of the product and the recall process is completed.

During the year ended March 31, 2022, USFDA issued a letter to the Group to test for the presence of Azide impurity(s) in Losartan. The Azide impurities are API process impurity(s), with the API supplier also receiving a similar letter from USFDA. The results confirmed the presence of Azide impurity(s) in the batches tested. As a result, the Group recalled specific batches which had the Azide impurity(s).

During the quarter and half ended September 30, 2026, and previous year ended March 31, 2026, with respect to the above mentioned recalls, the Group is carrying sufficient provision for sales return and has recorded an amount of Rs. 13.52 million, Rs. 27.84 million and Rs. 54.17 million respectively, towards other expenses related to its product withdrawal and settlements. Furthermore, the expenses recorded also include legal fees incurred by the Group in respect of its ongoing litigations with respect to these recalled products. These amounts, in line with earlier periods, have been recorded as an expense within Exceptional Items in the statement of profit and loss during the period.

During the year ended March 31, 2025, the Group voluntarily initiated recall of testosterone due to the presence of trace amounts of Benzene and during the previous year ended March 31, 2026, the Group has successfully relaunched the Product to ensure conformance with the FDA's updated requirements. The Group had received certain complaints which are legal in nature and are under evaluation. Accordingly the Group has created a provision of Rs. 3.52 million, Rs. 99.30 million and Rs.174.62 million towards the recall and other related expense which has been presented in exceptional items in the Statement of profit and loss during the quarter and half ended September 30, 2026, and previous year ended March 31, 2026 respectively, in line with earlier periods.

**STRIDES PHARMA SCIENCE LIMITED**

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS**FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026**

- 7 During the previous year ended March 31, 2026, the Company sold its investment property consisting of land and building for a consideration of Rs.1,128.70 million and recorded a profit of Rs.1,021.43 million as other income and the corresponding tax impact is considered as part of tax expense in the statement of profit and loss.

8 Information on Standalone Results : -**Rs. in Million**

Particulars	3 Months ended September 30, 2026	Preceding 3 Months ended June 30, 2026	Corresponding 3 Months ended in the previous year September 30, 2025	Year to date figures for the period ended September 30, 2026	Year to date figures for the previous period ended September 30, 2025	Previous year ended March 31, 2026
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total Income from continuing operations	6,612.89	5,841.23	5,362.44	12,454.12	10,366.18	23,031.98
Profit/ (loss) before tax from continuing operations	172.30	847.58	253.88	1,019.88	417.91	2,031.01
Profit/ (loss) after tax from continuing operations	92.63	729.28	320.40	821.91	453.87	1,836.35

- 9 The Board of Directors, at its meeting held on May 18, 2026, recommended a final dividend of ₹5 per equity share. Following approval by the shareholders at the Annual General Meeting, the dividend payment resulted in a cash outflow of approximately ₹461 million during the quarter.

For and on behalf of the Board**KOMANDUR
BADREE** Digitally signed by
KOMANDUR BADREE
Date: 2026.10.29
17:08:19 +05'30'**Badree Komandur****Managing Director and Group CEO****Bangalore, October 29, 2026**

Limited Review Report on unaudited standalone financial results of Strides Pharma Science Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Strides Pharma Science Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Strides Pharma Science Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP**Chartered Accountants**

Firm's Registration No.:101248W/W-100022

 Digitally signed
by G PRAKASH
Date: 2026.10.29
17:22:10 +05'30'**G Prakash****Partner**

Bangalore

29 October 2026

Membership No.: 099696

UDIN:26099696PVYJJJ6265

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

Rs. in Million							
Sl. No.	Particulars	3 Months ended September 30, 2026	Preceding 3 Months ended June 30, 2026	Corresponding 3 Months ended in the previous year September 30, 2025	Year to date figures for the current period ended September 30, 2026	Year to date figures for the previous period ended September 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
	Continuing Operations						
	Income						
I	Revenue from operations	6,599.07	5,826.48	5,221.52	12,425.55	10,207.68	21,801.35
II	Other income(Refer note 4)	13.82	14.75	140.92	28.57	158.50	1,230.63
III	Total income (I + II)	6,612.89	5,841.23	5,362.44	12,454.12	10,366.18	23,031.98
IV	Expenses						
	(a) Cost of materials consumed	3,032.09	3,091.06	2,556.60	6,123.15	4,666.37	10,195.97
	(b) Purchases of stock-in-trade	445.36	509.51	300.07	954.87	457.55	793.96
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	170.24	(557.85)	(36.45)	(387.61)	118.16	110.22
	(d) Employee benefits expense	1,079.22	1,024.01	964.88	2,103.23	1,905.28	3,816.02
	(e) Finance costs	277.64	285.09	294.13	562.73	598.61	1,137.68
	(f) Depreciation and amortisation expense	278.06	257.28	215.14	535.34	436.52	912.38
	(g) Other expenses	1,157.98	1,148.56	814.19	2,306.54	1,765.78	4,034.74
	Total expenses (IV)	6,440.59	5,757.66	5,108.56	12,198.25	9,948.27	21,000.97
V	Profit before exceptional items and tax (III - IV)	172.30	83.57	253.88	255.87	417.91	2,031.01
VI	Exceptional item(Refer note 5)	-	764.01	-	764.01	-	-
VII	Profit before tax (V + VI)	172.30	847.58	253.88	1,019.88	417.91	2,031.01
VIII	Tax expense/(benefit)						
	- Current tax	50.89	147.73	(113.69)	198.62	(114.16)	169.95
	- Deferred tax	28.78	(29.43)	47.17	(0.65)	78.20	24.71
	Total tax expense/(benefit) (VIII)	79.67	118.30	(66.52)	197.97	(35.96)	194.66
IX	Profit for the period/year (VII - VIII)	92.63	729.28	320.40	821.91	453.87	1,836.35



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026**

Sl. No.	Particulars	Rs. In Million				
		3 Months ended September 30, 2026	Preceding 3 Months ended June 30, 2026	Corresponding 3 Months ended in the previous year September 30, 2025	Year to date figures for the current period ended September 30, 2026	Year to date figures for the previous period ended September 30, 2025
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(6)
X	Other comprehensive income					
A	(i) Items that will not be reclassified to statement of profit and loss	-	-	-	-	46.48
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	-	-	-	-	(37.88)
B	(i) Items that may be reclassified to statement of profit and loss	150.86	310.78	(301.87)	461.64	(776.28)
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	(37.97)	(78.22)	105.48	(116.19)	200.81
	Total other comprehensive (loss)/ income, net of tax for the period/year (X)	112.89	232.56	(196.39)	345.45	(566.87)
XI	Total comprehensive income for the period/year (IX + X)	205.52	961.84	124.01	1,167.36	1,269.48
	Earnings per equity share (face value of Rs. 10/- each)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic (Rs.)	1.00	7.91	3.48	8.92	19.92
	(b) Diluted (Rs.)	1.00	7.91	3.48	8.92	19.92
	See accompanying notes to the Standalone Results					



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

STANDALONE BALANCE SHEET

		Rs. in Million	
	Particulars	As at September 30, 2026	As at March 31, 2026
		UNAUDITED	AUDITED
A	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	6,059.14	6,058.48
	(b) Capital work in progress	1,229.36	839.88
	(c) Right of Use Assets	215.93	283.52
	(d) Goodwill	1,155.77	1,155.77
	(e) Other intangible assets	788.72	350.50
	(f) Intangibles assets under development	712.52	973.12
	(g) Financial assets		
	(i) Investments	18,620.03	18,682.83
	(ii) Other financial assets	393.66	354.15
	(h) Deferred tax assets (net)	1,025.04	1,140.57
	(i) Income tax assets (net)	57.49	155.72
	(j) Other non-current assets	296.44	226.73
	Total non-current assets	30,554.10	30,221.27
II	Current assets		
	(a) Inventories	7,016.09	5,802.70
	(b) Financial assets		
	(i) Trade receivables	16,957.72	15,212.83
	(ii) Cash and cash equivalents	227.74	161.71
	(iii) Other balances with banks	91.86	245.10
	(iv) Loans	74.63	72.57
	(v) Other financial assets	666.23	319.70
	(c) Other current assets	2,575.03	1,921.31
	Total current assets	27,609.30	23,735.92
	Total assets	58,163.40	53,957.19



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

STANDALONE BALANCE SHEET

		Rs. in Million	
	Particulars	As at September 30, 2026 UNAUDITED	As at March 31, 2026 AUDITED
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity Share capital	921.73	921.73
	(b) Other equity	32,625.08	31,913.45
	Total Equity	33,546.81	32,835.18
II	Liabilities		
1	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	2,244.78	1,732.50
	(ii) Lease liabilities	159.70	182.45
	(iii) Other financial liabilities	304.34	264.32
	(b) Provisions	531.47	542.00
	Total Non-current liabilities	3,240.29	2,721.27
2	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	11,867.14	9,748.92
	(ii) Lease liabilities	125.12	178.54
	(iii) Trade payables		
	(a) total outstanding dues of micro enterprises and small enterprises and	815.69	430.22
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	7,069.12	6,425.68
	(iv) Other financial liabilities	875.33	1,252.13
	(b) Current tax liabilities	75.94	-
	(c) Other current liabilities	302.18	142.34
	(d) Provisions	245.78	222.91
	Total current liabilities	21,376.30	18,400.74
	Total liabilities	24,616.59	21,122.01
	Total equity and liabilities	58,163.40	53,957.19



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 STANDALONE STATEMENT OF CASH FLOWS

Rs. In Million

Sl. No.	Particulars	For the half year ended September 30, 2026	For the half year ended September 30, 2025	For the year ended March 31, 2026
		UNAUDITED	UNAUDITED	AUDITED
A.	Cash flow from operating activities			
	Profit before tax			
	Continuing operations	1,019.88	417.91	2,031.01
		1,019.88	417.91	2,031.01
	Adjustments for:			
	- Depreciation and amortisation expense	535.34	436.52	912.38
	- (Gain)/ Loss on sale/write off of property, plant and equipment, Investment Property and other intangible assets (net)	1.84	(0.42)	(1,027.65)
	- Provision for impairment of non current investments	-	-	23.13
	- Share based compensation expense	0.88	1.68	3.14
	- Finance costs	562.73	598.61	1,137.68
	- Interest income	(24.68)	(141.29)	(159.84)
	- Rental income	(0.36)	(8.76)	(9.50)
	- Loss allowance on trade receivables	(55.00)	(5.00)	25.00
	- Write off of advances to related party	-	-	86.74
	- Movement in inventory obsolescence	316.66	-	(87.60)
	- Gain on writing off of ROU asset and liability	-	(2.65)	(25.94)
	- Gain on sale of investment in subsidiary	(764.01)	-	-
	- Net unrealised exchange (gain)/ loss	(284.17)	(391.27)	(421.96)
	Operating profit before working capital changes	1,309.11	905.33	2,486.59
	Changes in working capital:			
	(Increase)/ Decrease in trade and other receivables	(2,142.49)	288.64	(269.80)
	Increase in inventories	(1,530.08)	(1,386.31)	(1,397.97)
	Increase/ (Decrease) in trade and other payables	1,204.23	1,253.68	1,972.60
	Net change in working capital	(2,468.34)	156.01	304.83
	Cash generated from operations	(1,159.23)	1,061.34	2,791.42
	Income taxes (paid)/ refund, net	(14.02)	216.01	(12.97)
	Net cash flow (utilised)/ generated from operating activities	(1,173.25)	1,277.35	2,778.45

A



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS **FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026** **STANDALONE STATEMENT OF CASH FLOWS**

Rs. In Million

Sl. No.	Particulars	For the half year ended September 30, 2026	For the half year ended September 30, 2025	For the year ended March 31, 2026
		UNAUDITED	UNAUDITED	AUDITED
B.	Cash flow from investing activities			
	Acquisition for property, plant and equipment and intangible assets, including capital advance and capital creditors	(1,124.69)	(704.58)	(1,635.71)
	Proceeds from sale of property, plant and equipment and intangible assets	0.92	2.50	16.08
	Proceeds from sale of investment property (net)	-	-	1,128.70
	Refund of proceeds for sale of assets	-	(50.00)	-
	Investments in subsidiaries and others	-	-	(229.08)
	(Advance refunded)/ Advance received for sale of investment property	-	-	(50.00)
	Proceeds from sale of investment in subsidiary	750.00	-	-
	Interest received (net of taxes)	8.71	0.81	0.81
	Dividend received	-	84.94	84.94
	Rental income from investment property	0.36	8.76	9.50
	Investment in fixed deposits with maturity of more than 3 months, net	70.25	-	(15.95)
	Net cash flow utilised in investing activities	(294.45)	(657.57)	(690.71)
	B			



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 STANDALONE STATEMENT OF CASH FLOWS

Rs. In Million

Sl. No.	Particulars	For the half year ended September 30, 2026	For the half year ended September 30, 2025	For the year ended March 31, 2026
		UNAUDITED	UNAUDITED	AUDITED
C.	Cash flow from financing activities			
	Proceeds from issue of equity shares	-	3.87	3.86
	Proceeds from share application money pending allotment	4.25	-	-
	Proceeds from long-term borrowings	801.25	574.79	1,065.57
	Repayment of long-term borrowings	(261.50)	(423.21)	(794.62)
	Proceeds/(Repayment) from short-term borrowings	2,088.36	287.28	(625.72)
	Dividends paid	(460.87)	(368.65)	(368.65)
	Lease payments	(76.18)	(65.30)	(133.90)
	Interest on Lease liability paid	(17.68)	(22.81)	(44.93)
	Interest paid on borrowings	(543.89)	(580.49)	(1,090.92)
	Net cash flow generated/(utilised) in financing activities	1,533.74	(594.52)	(1,989.31)
	Net increase/ (decrease) in cash and cash equivalents during the year	66.04	25.26	98.43
	Cash and cash equivalents at the beginning of the year	161.71	63.28	63.28
	Cash and cash equivalents at the end of the year*	227.75	88.54	161.71
	* Comprises:			
	Cash on hand	2.36	2.15	2.10
	Balance with banks:			
	- In current accounts	10.94	10.85	10.94
	- Funds-in-transit	214.45	75.54	148.67
	Total	227.75	88.54	161.71

**STRIDES PHARMA SCIENCE LIMITED**

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026****Notes:**

- 1 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 29, 2026. The statutory auditor has carried out a limited review of the above results for the quarter and half year ended September 30, 2026 and has issued an unmodified opinion.
- 3 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Company's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments.

The CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. "Pharmaceutical". The Company publishes standalone and consolidated financial results. Pursuant to Paragraph 4 of Ind AS 108, Operating Segments, the segment information has been disclosed in the consolidated financial results. Accordingly, no separate segment information is presented in these standalone financial results.

Pharmaceutical segment represents the business of development, manufacture and commercialization of pharmaceutical products other than biological drugs.

- 4 During the previous year ended March 31, 2026, the Company sold its investment property consisting of land and building for a consideration of Rs.1,128.70 million and recorded a profit of Rs.1,021.43 million as other income and the corresponding tax impact is considered as part of tax expense in the statement of profit and loss.
- 5 On March 19, 2025, the Board of Directors of the Company approved the demerger of the Life Sciences and Digital Innovation capabilities business of Arco Lab Private Limited ("Arco Lab"), a subsidiary of the Company, into Pivot Path Private Limited ("Pivot Path"), a subsidiary of Arco Lab, pursuant to a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The Scheme, approved by the Board of Directors of Arco Lab on May 15, 2025, with an appointed date of April 10, 2025, was approved by the Hon'ble National Company Law Tribunal (NCLT) on May 18 2026 and the scheme was made effective pursuant to ROC filings effective June 1, 2026.

In the previous quarter, the Board of Directors of the Company approved the dilution of the Company's stake in Pivot Path to incoming investors for an aggregate consideration of ₹ 1,000 million. Upon completion of the transaction on June 30, 2026, the Group's shareholding in Pivot Path reduced to 19.95% and the Group ceased to have control over Pivot Path. The transaction also included as a condition precedent, on the execution of a five-year Master Services Agreement with Pivot Path containing minimum revenue commitment and annual price escalation arrangement. Accordingly, the Company recognized a net gain of ₹ 764.01 million, which has been disclosed as an exceptional item in these financial results.

- 6 The Board of Directors, at its meeting held on May 18, 2026, recommended a final dividend of ₹5 per equity share. Following approval by the shareholders at the Annual General Meeting, the dividend payment resulted in a cash outflow of approximately ₹461 million during the quarter.

Bangalore, 29 October 2026**For and on behalf of the Board****KOMANDUR
BADREE**Digitally signed by
KOMANDUR BADREE
Date: 2026.10.29
17:02:56 +05'30'**Badree Komandur**
Managing Director and Group CEO